Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | TRPC3 | Q13507 | 3/20 | 0.39 |
| ▸ | ORAI1 | Q96D31 | 3/20 | 0.38 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.34 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2884049 | 0.93 | TP53 (0.36) | TP53TRPC3ORAI1TRPC5PTGS1 | |
| SCHEMBL2884293 | 0.91 | GRM1 (0.37) | GRM1GRM4LMNASMN1; SMN2TYMS | |
| SCHEMBL2884223 | 0.91 | PTGS1 (0.37) | PTGS1PTGS2GRM1GRM4LMNA | |
| SCHEMBL2892164 | 0.88 | TP53 (0.39) | TP53TRPC3ORAI1TRPC5PTGS1 | |
| SCHEMBL2887621 | 0.88 | GRM1 (0.46) | TP53TRPC3ORAI1TRPC5PTGS1 | |
| SCHEMBL2883863 | 0.83 | MAPT (0.38) | GRM1GRM4MAPTLMNASMN1; SMN2 | |
| SCHEMBL1835277 | 0.82 | GRIA2 (0.39) | GRM1GRM4LMNASMN1; SMN2 | |
| SCHEMBL2887951 | 0.80 | GRM1 (0.36) | GRM1GRM4LMNASMN1; SMN2TYMS | |
| SCHEMBL5716818 | 0.79 | F10 (0.34) | GRM1GRM4 | |
| SCHEMBL2884079 | 0.78 | GRM1 (0.35) | GRM1GRM4LMNASMN1; SMN2TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130743-A1 | HETEROCYCLE-SUBSTITUTED, N-PHENYL-PHTHALAMIDE DERIVATIVES, RELATED COMPOUNDS AND THEIR USE AS INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2010-05-27 | — | — | US | disclosed |
| US-7674807-B2 | Heterocycle-substituted n-phenyl-phthalamide derivatives, related compounds and their use as insecticides | BAYER CROPSCIENCE AG (DE) | 2010-03-09 | — | — | US | disclosed |
| US-20070299085-A1 | N1-((Pyrazol-1-Ymethyl)-2-Methylphenyl)-Phatalamide Derivatives And Related Compounds Insecticides | BAYER CROPSCIENCE AG (DE) | 2007-12-27 | — | — | US | disclosed |
| EP-1727804-A1 | N1 - ((PYRAZOL-1-YMETHYL) -2-METHYLPHENYL)- PHATALAMIDE DERIVATIVES AND RELATED COMPOUNDS INSECTICIDES | Bayer CropScience Aktiengesellschaft (DE) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005095351-A1 | N1 - ((PYRAZOL-1-YMETHYL) -2-METHYLPHENYL)- PHATALAMIDE DERIVATIVES AND RELATED COMPOUNDS INSECTICIDES | BAYER CROPSCIENCE AG (DE) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130743-A1 | HETEROCYCLE-SUBSTITUTED, N-PHENYL-PHTHALAMIDE DERIVATIVES, RELATED COMPOUNDS AND THEIR USE AS INSECTICIDES | DDT, SQOR, CYP2S1 | TP53 3565/4885TRPC3 2181/4885ORAI1 3747/4885 |
| US-20070299085-A1 | N1-((Pyrazol-1-Ymethyl)-2-Methylphenyl)-Phatalamide Derivatives And Related Compounds Insecticides | CHRM1, KCNH1, DDT | TP53 4654/4885TRPC3 1643/4885ORAI1 2206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.